Dr Reddys Laboratories (RDY) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.72 Bn | 39.07 Bn | 2.15 Bn | 8.25% |
| 2 | Viatris | 19.14 Bn | 18.26 Bn | 1.46 Bn | -10.08% |
| 3 | Dr Reddys Laboratories | 9.89 Bn | 9.71 Bn | 396.53 Mn | -27.48% |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.34 Bn | 334.51 Mn | -23.26% |
| 5 | Bausch Health Companies | 2.33 Bn | 494.50 Mn | 2.10 Bn | 48.16% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 40.06% |
| 8 | Amphastar Pharmaceuticals | 994.43 Mn | 704.31 Mn | 93.47 Mn | -2.23% |
| 9 | Fennec Pharmaceuticals | 399.34 Mn | 358.09 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.33 Mn | 178.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.48% |
| Sep 30, 2025 | 15.33% |
| Jun 30, 2025 | 25.58% |
| Sep 30, 2024 | 17.30% |
| Jun 30, 2024 | 61.06% |
| Mar 31, 2024 | -3.53% |
| Dec 31, 2023 | -0.53% |
| Sep 30, 2023 | 20.40% |
| Jun 30, 2023 | -1.55% |
| Mar 31, 2023 | 89.56% |
| Dec 31, 2022 | 40.01% |
| Sep 30, 2022 | -6.71% |
| Jun 30, 2022 | -15.12% |
| Mar 31, 2022 | 8.43% |
| Dec 31, 2021 | 0.85% |
| Sep 30, 2021 | -23.36% |
| Jun 30, 2021 | 14.56% |
| Mar 31, 2021 | 19.80% |
| Dec 31, 2020 | -20.76% |
| Sep 30, 2020 | 5.99% |